JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cornfield, L. J.
Right arrow Articles by Sills, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cornfield, L. J.
Right arrow Articles by Sills, M. A.

[3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain

LJ Cornfield, S Hu, SD Hurt and MA Sills

Research Department, CIBA-GEIGY Corporation, Summit, New Jersey.

Earlier studies have demonstrated that the vasoactive compound CV 1808 displays 10-fold selectivity for the adenosine A2 receptor, and as such, was the first reported A2-selective agonist. After the radiolabeling of CV 1808, its binding characteristics were evaluated in rat striatal, cortical and hippocampal membranes. Using 5 nM [3H]CV 1808, unlabeled CV 1808 produced shallow inhibition curves in all three brain areas, with 61 to 75% of the binding displaying IC50 values of 16 to 24 nM, whereas the remaining 28 to 37% of binding had lower affinity (IC50 595-1130 nM). The A2-selective agonist CGS 21680 and the nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine displayed very low affinity (IC50 > 10 microM). The A1-selective compound N6- cyclopentyladenosine inhibited only 28 to 44% of specific binding, with IC50 of 272-1750 nM. In contrast, the nonselective adenosine antagonist CGS 15943A inhibited specific binding by 48 to 64% (at 1 microM) with IC50 ranging from 106 to 295 nM. Additionally, several novel adenosine analogs fully inhibited specific binding, producing multicomponent inhibition curves. Electrophysiological studies in porcine coronary artery cells demonstrated that CV 1808, but not CGS 21680, 5'-N- ethylcarboxamidoadenosine and N6-cyclopentyladenosine, activated potassium channels. Further, the CV 1808-induced activation was blocked by CGS 15943A. These results indicate that [3H]CV 1808 binding consists of two components in rat brain: a low-affinity site with A1-like characteristics, and a novel high-affinity site, designated as the A4 receptor, where potassium channel activation appears to be a functional correlate.

Volume 263, Issue 2, pp. 552-561, 11/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
E. M. Schwiebert and B. K. Kishore
Extracellular nucleotide signaling along the renal epithelium
Am J Physiol Renal Physiol, June 1, 2001; 280(6): F945 - F963.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. Tang, M. Parker, Q. Fei, and R. Loutzenhiser
Afferent arteriolar adenosine A2a receptors are coupled to KATP in in vitro perfused hydronephrotic rat kidney
Am J Physiol Renal Physiol, December 1, 1999; 277(6): F926 - F933.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
V. Ralevic and G. Burnstock
Receptors for Purines and Pyrimidines
Pharmacol. Rev., September 1, 1998; 50(3): 413 - 492.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1992 by the American Society for Pharmacology and Experimental Therapeutics.